Stay updated on Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, indicating a small update to the page version.SummaryDifference0.1%

- Check16 days agoChange DetectedThe page now shows Revision: v3.6.2, replacing the previous v3.6.0, indicating an updated page version.SummaryDifference0.1%

- Check30 days agoChange DetectedRecruitment status now indicates no participants are being sought, and new guidance sections were added to help users read the study record and join the study. The revision tag was updated to v3.6.0 and the Intervention/Treatment heading formatting was adjusted.SummaryDifference0.6%

- Check37 days agoChange DetectedThe page revision label was updated from v3.5.4 to v3.5.5, indicating a minor update to the page version.SummaryDifference0.1%

- Check59 days agoChange Detected- The page now displays Revision: v3.5.4, replacing v3.5.3. This indicates a version update to the page's revision metadata.SummaryDifference0.1%

- Check80 days agoChange DetectedThe page’s interface/release revision updated from **v3.5.2** to **v3.5.3**.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs. EDP1503 in Melanoma Clinical Trial page.